Penumbra Brand Guidelines: Alameda 2004, Indigo, Lightning & a Pending Boston Scientific Sale

Two founders and an aspiration pump.

Penumbra was founded in 2004 by Arani Bose and Adam Elsesser, English Wikipedia says, and has its headquarters in Alameda, California, on San Francisco Bay. The company itself says it was founded in 2004 in Alameda. Its earliest filings with the U.S. Food and Drug Administration, from 2005 to 2007, give its address as neighbouring San Leandro, and the Alameda address appears in FDA records from 2008. Elsesser is Penumbra’s chairman and chief executive, Boston Scientific’s January 2026 announcement says.

The FDA’s 510(k) database traces how the product line grew. The first clearance listed under Penumbra’s name, in August 2005, is for an aspiration pump; a balloon guide catheter followed in 2006, the Neuron catheter system in 2007 and the Penumbra System in December 2007. Embolization coils were cleared in January 2011 and the Apollo System in January 2014; English Wikipedia says Apollo launched that year for the minimally invasive removal of tissue and fluid in the brain. In May 2015 the FDA cleared the Indigo Aspiration System, the name under which most of Penumbra’s vascular thrombectomy products have been filed since. The database now holds more than 80 clearances under the company’s name.

Penumbra went public on the New York Stock Exchange in 2015, Wikipedia says, and trades under the ticker PEN. Wikipedia also records its purchase of the Italian distributor Crossmed in 2017 and a 40% stake in the virtual-reality joint venture MVI Health in 2018.

Indigo, Lightning and Thunderbolt.

Penumbra works on two fronts. Its website sorts the catalogue into neuro and vascular, and Boston Scientific’s January 2026 announcement described a portfolio covering access, stroke revascularization and neuro embolization on one side, and mechanical thrombectomy and peripheral embolization on the other. The company describes itself on its about page as one that “designs, develops, manufactures and markets” its products, and says it has more than 4,700 employees and sells in more than 100 markets.

Several product names come from storms. Lightning aspiration tubing first appears in FDA records in 2020, Lightning Flash in December 2022 and Lightning Bolt in February 2023. Boston Scientific described Lightning Bolt and Lightning Flash as “computer assisted vacuum thrombectomy (CAVT™) systems” used in peripheral procedures to remove clots from arterial, venous and pulmonary vessels. The newest, Thunderbolt tubing, was cleared in June 2026; Penumbra’s homepage calls it “the latest Penumbra CAVT platform” and, in the company’s words, the first and only cleared technology to use modulated aspiration for stroke thrombectomy. Coils take a gemstone name: the Ruby Coil System, cleared in 2018 alongside POD and the Penumbra Coil 400, and the Ruby XL in 2025.

The homepage tagline is “Innovating with Purpose,” and the newsroom shows the pace of late 2026: in September Penumbra announced the launch of Link, which it says expands vascular thrombectomy options, and in October it said its CAVT technology had received FDA clearance for the treatment of deep vein thrombosis.

The FDA recall database records several Penumbra recalls. One began on 15 December 2020 and covered JET 7 reperfusion catheters over possible damage to the distal tip during use; the FDA lists it as terminated. Recalls of the Penumbra Coil 400 in 2011 and of the 3D Revascularization Device in 2017 are also closed, while recalls of specific lots of RED 68 and RED 62 reperfusion catheters, begun in June and July 2026, are listed as open.

Design and documentation.

Cardiovascular device makers sell to a narrow audience: interventional cardiologists, electrophysiologists, cardiac surgeons, hospital buyers and regulators. Their visual language follows from that. A heart valve, a stent or a pacemaker is small, precise and usually hidden inside the body once it is in use, so the product photograph does much of the work. Valves, stents and leads tend to be shot in close-up on white or pale grey, lit to show struts, mesh and metal edges, with the device itself as the only subject.

The second register is the catheterisation laboratory. Brochures, websites and congress stands return again and again to the same scene: a patient table, a C-arm X-ray system arched over it, banks of monitors showing angiograms or mapping images, and clinicians in scrubs, lead aprons and caps. These pictures place the device in the room where it is used, without showing the patient’s body in detail.

Between the two sits illustration. Cutaway hearts, cross-sections of arteries and simplified diagrams of the conduction system explain where a valve sits, how a stent opens or how a lead reaches the heart. They are often rendered in reds and soft pinks against white, with the brand’s own colour kept for the device, the arrows and the type. Much of the copy is technical, built around product names, trial names and regulatory approvals as the companies state them.

Much of the category’s public life happens at medical congresses. TCT in the United States, EuroPCR in Paris and the ESC Congress of the European Society of Cardiology bring makers, clinicians and trade press together each year, and companies use them to show new devices and announce study results. The makers in this guide range from family-owned German engineering firms to Chinese groups with several listed subsidiaries, and their identities reflect that range more than any shared house style.

Still listed, with a sale to Boston Scientific agreed.

Penumbra remains an independent listed company for now, with a sale pending. On 15 January 2026 Boston Scientific and Penumbra announced a definitive agreement under which Boston Scientific will acquire Penumbra in a cash-and-stock transaction, approved by the boards of both companies. Boston Scientific said the purchase would let it enter new, fast-growing segments of the vascular market, and that Elsesser would join its board once the deal closed.

The release said the transaction was expected to be completed in 2026, subject to Penumbra’s stockholder approval and other customary closing conditions, and listed the receipt of regulatory approvals and clearances among the conditions. The deal was agreed in January 2026 and had not been completed at the time of writing. English Wikipedia says it was expected to close by the end of the year, and Penumbra’s website still carries its own name and copyright line.

Until the deal closes, the Penumbra name sits above a set of sub-brands. Indigo, Lightning, Thunderbolt and Ruby each appear in FDA filings under the Penumbra name, and Thunderbolt is the featured product on the company’s homepage. Elsesser, in Boston Scientific’s announcement, spoke of the company’s “decades-long development of therapies for challenging medical conditions.”

For a design guide, Penumbra shows how one company can build a family of product names around a single theme while the company name stays above them. Compare Boston Scientific, which has agreed to buy it, and Stryker. For this guide we use an eclipse plum, an umbra grey and a bolt amber with a serif, an unofficial interpretation; no product or logo is reproduced.

Keep Penumbra’s identity on hand — save it to a board in the Made Good inspiration library.